Clinical Trials
9 trialsNCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT03919292 2026-04-21
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
Phase 1/2 Recruiting
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05274048 2025-10-29
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
Phase 1 Recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06519110 2024-07-25
CVL009-C2001
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT01960023 2021-10-27
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 1/2 Withdrawn